1932

Abstract

The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral eradication rates are pushing 100% for many HCV-infected populations, including patients with HIV/HCV coinfection, decompensated cirrhosis, liver and kidney transplants, and end-stage liver disease. We highlight the greatest successes of combination DAA therapies, discuss the ongoing challenges, and identify the remaining patient subgroups with unmet medical needs.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-052915-015720
2017-01-14
2024-04-13
Loading full text...

Full text loading...

/deliver/fulltext/med/68/1/annurev-med-052915-015720.html?itemId=/content/journals/10.1146/annurev-med-052915-015720&mimeType=html&fmt=ahah

Literature Cited

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 1.  2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–42 [Google Scholar]
  2. Wong RJ, Aguilar M, Cheung R. 2.  et al. 2015. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148:547–55 [Google Scholar]
  3. Ly KN, Hughes EM, Jiles RB, Holmberg SD. 3.  2016. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin. Infect. Dis. 62:1287–88 [Google Scholar]
  4. Mallet V, Gilgenkrantz H, Serpaggi J. 4.  et al. 2008. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 149:399–403 [Google Scholar]
  5. McHutchison JG, Lawitz EJ, Shiffman ML. 5.  et al. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580–93 [Google Scholar]
  6. Chung RT, Andersen J, Volberding P. 6.  et al. 2004. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351:451–59 [Google Scholar]
  7. Muir AJ, Bornstein JD, Killenberg PG. 7.  for the Atlantic Coast Hepatitis Treatment Group 2004. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 350:2265–71 [Google Scholar]
  8. Berry PA, Thomson SJ. 8.  2013. The patient presenting with decompensated cirrhosis. Acute Med 12:232–38 [Google Scholar]
  9. 9. Victrelis [package insert]. Whitehouse Station, NJ: Merck & Co., Inc 2011.
  10. 10. Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals, Inc 2011.
  11. 11. Olysio [package insert]. Titusville, NJ: Janssen Therapeutics 2013.
  12. 12. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2013.
  13. 13. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc 2014.
  14. 14. Viekira Pak [package insert]. North Chicago, IL: AbbVie, Inc 2014.
  15. 15. Technivie [package insert]. North Chicago, IL: AbbVie, Inc 2015.
  16. 16. Daklinza [package insert]. Princeton, NJ: Bristol-Myers Squibb 2015.
  17. 17. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co., Inc 2016.
  18. 18. NEW N/A [package insert]. Foster City, CA: Gilead Sciences, Inc 2016.
  19. Smith DB, Bukh J, Kuiken C. 19.  et al. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318–27 [Google Scholar]
  20. Nelson DR, Cooper JN, Lalezari JP. 20.  et al. 2015. All-oral 12-week treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology 61:1127–35 [Google Scholar]
  21. Konerman MA, Mehta SH, Sutcliffe CG. 21.  et al. 2014. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 59:3767–75 [Google Scholar]
  22. Smith CJ, Ryom L, Weber R. 22.  et al. 2014. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384:9939241–48 [Google Scholar]
  23. Naggie S, Cooper C, Saag M. 23.  et al. 2015. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N. Engl. J. Med. 373:8705–13 [Google Scholar]
  24. Mehta SH, Lucas GM, Mirel LB. 24.  et al. 2006. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 20:182361–69 [Google Scholar]
  25. Torriani FJ, Rodriguez-Torres M, Rockstroh JK. 25.  et al. 2004. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351:438–50 [Google Scholar]
  26. Dieterich D, Rockstroh JK, Orkin C. 26.  et al. 2014. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin. Infect. Dis. 59:111579–87 [Google Scholar]
  27. Rodriguez-Torres M, Gaggar A, Shen G. 27.  et al. 2015. Sofosbuvir for chronic hepatitis C virus infection genotype 1–4 in patients coinfected with HIV. J. Acquir. Immune Defic. Syndr. 68:543–49 [Google Scholar]
  28. Wyles DL, Ruane PJ, Sulkowski MS. 28.  et al. 2015. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N. Engl. J. Med. 373:8714–25 [Google Scholar]
  29. Rockstroh JK, Nelson M, Katlama C. 29.  et al. 2015. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2:8e319–27 [Google Scholar]
  30. Wyles D, Brau N, Kottilil S. 30.  et al. 2016. Sofosbuvir/velpatasvir for 12 weeks in patients coinfected with HCV and HIV-1: the ASTRAL-5 study. Presented at Int. Congr. Eur. Assoc. Stud. Liver Disease, Apr. 13–17, Barcelona, Spain
  31. 31. US Food and Drug Administration 2016. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. Guidance for industry. May 2016 draft. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf
  32. Fink SA, Jacobson IM. 32.  2011. Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 8:285–95 [Google Scholar]
  33. Charlton M, Ruppert K, Belle SH. 33.  et al. 2004. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 10:1120–30 [Google Scholar]
  34. Berenguer M, Prieto M, Rayon JM. 34.  et al. 2000. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32:852–58 [Google Scholar]
  35. Forman LM, Lewis JD, Berlin JA. 35.  et al. 2002. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122:889–96 [Google Scholar]
  36. Forns X, Charlton M, Denning J. 36.  et al. 2015. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61:51485–94 [Google Scholar]
  37. Charlton M, Everson GT, Flamm SL. 37.  et al. 2015. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149:3649–59 [Google Scholar]
  38. Manns M, Samuel D, Gane EJ. 38.  et al. 2016. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect. Dis. 16:685–97 [Google Scholar]
  39. Poordad F, Schiff ER, Vierling JM. 39.  et al. 2016. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology 63:1493–505 [Google Scholar]
  40. Curry MP, O'Leary JG, Bzowej N. 40.  et al. 2015. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 373:272618–28 [Google Scholar]
  41. Gane EJ. 41.  2008. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 14:Suppl. 2S36–44 [Google Scholar]
  42. Curry MP, Forns X, Chung RT. 42.  et al. 2015. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148:1100–7 [Google Scholar]
  43. Afdhal N, Zeuzem S, Kwo P. 43.  et al. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370:201889–98 [Google Scholar]
  44. Afdhal N, Reddy KR, Nelson DR. 44.  et al. 2014. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370:161483–93 [Google Scholar]
  45. Noureddine LA, Usman SA, Yu Z. 45.  et al. 2010. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am. J. Nephrol. 32:311–16 [Google Scholar]
  46. Tsui JI, Vittinghoff E, Shlipak MG. 46.  et al. 2007. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch. Intern. Med. 167:1271–76 [Google Scholar]
  47. Fabrizi F, Dixit V, Messa P. 47.  2012. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?. J. Viral Hepat. 19:601–7 [Google Scholar]
  48. Pereira BJG, Wright TL, Schmid CH, Levey AS. 48.  1995. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 60:799–805 [Google Scholar]
  49. Burra P, Rodríguez-Castro KI, Marchini F. 49.  et al. 2014. Hepatitis C virus infection in end-stage renal disease and kidney transplantation. Transpl. Int. 27:9877–91 [Google Scholar]
  50. Roth D, Nelson DR, Bruchfeld A. 50.  et al. 2015. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386:100031537–45 [Google Scholar]
  51. Kusnir J, Roth D. 51.  2016. Direct-acting antiviral agents for the hepatitis C virus-infected chronic kidney disease population: the dawn of a new era. Semin. Dial. 29:5–6 [Google Scholar]
  52. Colombo M, Aghemo A, Liu H. 52.  et al. 2016. Ledipasvir/sofosbuvir (LDV/SOF) for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection Presented at Int. Congr. Eur. Assoc. Stud. Liver Disease, Apr. 13–17, Barcelona, Spain
  53. Foster GR, Afdhal N, Roberts SK. 53.  et al. 2015. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 373:2608–17 [Google Scholar]
  54. Gower E, Estes C, Blach S. 54.  et al. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61:S45–S57 [Google Scholar]
  55. Ampeuro J, Romero-Gomez M. 55.  2015. Current and evolving treatments for genotypes 2 and 3. Gastroenterol. Clin. N. Am. 44:845–57 [Google Scholar]
  56. Abenavoli L, Masarone M, Peta V. 56.  et al. 2014. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J. Gastroenterol. 20:4115233–40 [Google Scholar]
  57. Clark PJ, Thompson AJ, Vock DM. 57.  et al. 2012. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56:149–56 [Google Scholar]
  58. Scheel TKH, Rice CM. 58.  2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19:837–49 [Google Scholar]
  59. Kwo PY, Wyles DL, Wang S. 59.  et al. 2016. 100% SVR12 with ABT-493 and ABT-530 with or without ribavirin in treatment-naïve HCV genotype 3-infected patients with cirrhosis Presented at Int. Congr. Eur. Assoc. Stud. Liver Disease, Apr. 13–17, Barcelona, Spain
  60. Muir AJ, Strasser S, Wang S. 60.  et al. 2016. High SVR rates with ABT-493 + ABT-530 co-administered for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection Presented at Int. Congr. Eur. Assoc. Stud. Liver Disease, Apr. 13–17, Barcelona, Spain
  61. Rong L, Dahari H, Ribeiro RM, Perelson AS. 61.  2010. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2:30ra32 [Google Scholar]
  62. Howe AYM, Long J, Nickle D. 62.  et al. 2015. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antivir. Res. 113:71–78 [Google Scholar]
  63. Dvory-Sobol H, Wyles D, Ouyang W. 63.  et al. 2015. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J. Hepatol. 62:S221 [Google Scholar]
  64. Sarrazin C, Dvory-Sobol H, Svarovskaia E. 64.  et al. 2016. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 151:501–12 [Google Scholar]
  65. American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA); 2016. Recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org
  66. Lawitz E, Flamm S, Yang JC. 66.  et al. 2015. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks Presented at Annu. Meet. Eur. Assoc. Stud. Liver (EASL), 50th, Apr. 22–26, Vienna, Austria, Abstr. 0005
  67. Cooper C, Naggie S, Saag M. 67.  et al. 2016. Successful re-treatment of hepatitis C virus in patients coinfected with HIV who relapsed after 12 weeks of ledipasvir/sofosbuvir. Clin. Infect. Dis. 63:528–31 [Google Scholar]
  68. Schwarz K, Murray KF, Rosenthal P. 68.  et al. 2016. High rate of SVR in adolescents treated with the combination of ledipasvir/sofosbuvir Presented at Int. Congr. Eur. Assoc. Stud. Liver Disease, Apr. 13–17, Barcelona, Spain
/content/journals/10.1146/annurev-med-052915-015720
Loading
/content/journals/10.1146/annurev-med-052915-015720
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error